Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
Chanchai CharonpongsuntornSuebpong TanasanvimonKrittiya KorphaisarnSongwit PayapwattanawongTeerada SiripoonNussara PakvisalJitlada JuengsamarnEkkamol PhaibulvatanapongJarin ChindaprasirtNaiyarat PrasongsookKittipong UdomdamrongkulNuttapong NgamphaiboonEkaphop SirachainanPublished in: JCO global oncology (2022)
This study demonstrates that atezolizumab plus bevacizumab is effective and has a safety profile comparable with that of previous studies as first-line therapy for unresectable HCC in a real-world setting and in Thai populations. Data on PROs also demonstrate benefits in terms of patients' QoL and symptoms.
Keyphrases
- patient reported outcomes
- end stage renal disease
- ejection fraction
- newly diagnosed
- locally advanced
- chronic kidney disease
- metastatic colorectal cancer
- liver metastases
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- electronic health record
- cross sectional
- rectal cancer
- sleep quality
- data analysis
- case control